ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Biocon Biologics Gains Approval To Launch Bmab 1200 In Europe Uk Canada And Japan
News Feed
course image
  • 02 Sep 2024
  • Admin
  • News Article

Biocon Biologics Gains Approval to Launch Bmab 1200 in Europe, UK, Canada, and Japan

Overview

Biocon Biologics announced today that it has signed a settlement and license agreement with Janssen Biotech, Janssen Sciences, and Johnson & Johnson.

About Stelara

  • Stelara® (Ustekinumab) is a monoclonal antibody used to treat conditions such as psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis by targeting interleukin IL-12/23. 
  • In 2023, Stelara® generated global sales of $10.85 billion.

About Agreement

  • This agreement allows Biocon to commercialise its proposed biosimilar Bmab 1200, similar to Stelara®, in Europe, the United Kingdom, Canada, and Japan.
  • The agreement resolves patent disputes with Janssen and provides Biocon Biologics with confirmed market entry dates in these regions. 
  • The regulatory filings for Bmab 1200 in these markets are currently under review.

Settlement in the US

Previously, Biocon Biologics reached a settlement in the United States, securing a potential launch for Bmab 1200 no later than 22 February 2025, subject to approval by the U.S. Food and Drug Administration (FDA). 

FDA review- The FDA is currently reviewing the Company’s Biologics License Application (BLA) for Bmab 1200 under the 351(k) pathway.

Biocon Biologics' Commitment

This agreement highlights Biocon Biologics' commitment to scientific innovation and marks a significant milestone in bringing Bmab 1200 (bUstekinumab) to global markets.

The biosimilar Bmab 1200 will enhance the Company’s immunology portfolio, offering a cost-effective treatment option for patients with autoimmune diseases.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form